Zeda is a dedicated cancer researcher with expertise in drug resistance. He received his undergraduate training at NIBS, exploring programmed cell death mechanisms, and earned his Ph.D. at Memorial Sloan Kettering, focusing on antiandrogen resistance in prostate cancer. Recognized with the F99/K00 award from the National Cancer Institute, he is now a Damon Runyon Cancer Research Foundation Fellow at Howard Hughes Medical Institute, studying cell surface remodeling in cancer/wound healing and developing cell-based therapies to overcome immune evasion in ovarian/prostate cancer. Outside of research, he enjoys skiing, cycling, and marathon running.